Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY trial has been named David Sackett Trial of the Year by the Society for Clinical Trials. The award was presented today at the Society for Clinical Trials’ 42nd Annual Meeting.

Logo of the Society for Clinical Trials

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial is a large, pragmatic randomised trial for the treatment of hospitalised patients with suspected or confirmed COVID-19. It was designed and implemented at extraordinary speed in the midst of the COVID-19 pandemic, at a time of great need for effective treatments to reduce mortality among hospitalised patients.

Peter Horby, Professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the RECOVERY trial, said ‘This award is a testament and a tribute to the exceptional work of many thousands of people working under the most difficult circumstances. 2020 was awful in so many ways but the RECOVERY trial was uplifting, showing what can be achieved when there is unity, resolve and a commitment to good science. RECOVERY is a truly national achievement and every person involved should feel incredibly proud. I would encourage them to regularly remind themselves that there are many thousands of people who are only alive today thanks to their efforts.’ 

Every year since 2008, the Society for Clinical Trials has awarded the David Sackett Trial of the Year Award to a randomised, controlled trial published in the previous calendar year that best fulfills the following standards: improves the lot of humankind; provides the basis for a substantial, beneficial change in health care; reflects expertise in subject matter, excellence in methodology, and concern for study participants; overcomes obstacles in implementation; and based on the presentation of its design, execution, and results is a model of clarity and intellectual soundness.

The full story is available on the RECOVERY website

Similar stories

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

Systematic review identifies research gaps for Chagas disease

A new, large-scale systematic review published in PLOS Neglected Tropical Diseases has identified clear, significant research gaps in the diagnosis and treatment of Chagas disease. The paper also highlights significant differences in study design, diagnostic methods, duration of follow-up, and the timing of outcome assessment used by investigators even in the last decade.

Oxford retains top spot in world rankings for sixth consecutive year

The University of Oxford remains top of the table in latest Times Higher Education World University Rankings. In a year dominated by the ongoing Covid-19 pandemic, the rankings reflect the vital role of universities in understanding and managing the crisis as a number of institutions around the world saw significant boosts in their citation scores from Covid-19 focused research.

Royal Society Africa Prize 2021 awarded to George Warimwe

The Royal Society Africa Prize 2021 is awarded to Professor George Warimwe for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. This Prize recognises research scientists based in Africa who are making an innovative contribution to the sciences.

The scale of the problem of visceral leishmaniasis in pregnancy is underestimated

Despite the limitations and paucity of data, the most comprehensive review of visceral leishmaniasis to date in pregnant women and vertical transmission of leishmaniasis has confirmed that liposomal amphotericin B is the safest treatment option and it is critical to ensure access to this.

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.